Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tepotinib - Merck KGaA

Drug Profile

Tepotinib - Merck KGaA

Alternative Names: EMD-1214063; MSC-2156119; MSC-2156119J; TEPMETKO

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Class Antineoplastics; Nitriles; Piperidines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase II Colorectal cancer; Liver cancer
  • Discontinued Solid tumours

Most Recent Events

  • 30 Sep 2021 Biomarkers information updated
  • 12 Aug 2021 Merck KGaA completes the phase Ib/II INSIGHT trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China, Japan, Spain, Bulgaria, Netherlands, Slovakia, Italy, Malaysia, Malaysia, Singapore, South Korea, Taiwan (PO) (NCT01982955) (EudraCT2016-001604-28)
  • 30 Jun 2021 Merck initiates Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (PO) before June 2021 (NCT03940703)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top